Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Perspectives from ASCO 2018: Advances in Waldenström's macroglobulinemia, the iNNOVATE trial

Meletios Dimopoulos explains that the iNNOVATE trial in Waldenström's macroglobulinemia he presented at ASCO 2018 is a randomised phase III study testing the efficacy and safety of the combination ibrutinib/rituximab against rituximab/placebo.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings